JP2019501140A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501140A5
JP2019501140A5 JP2018527799A JP2018527799A JP2019501140A5 JP 2019501140 A5 JP2019501140 A5 JP 2019501140A5 JP 2018527799 A JP2018527799 A JP 2018527799A JP 2018527799 A JP2018527799 A JP 2018527799A JP 2019501140 A5 JP2019501140 A5 JP 2019501140A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018527799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501140A (ja
JP6882289B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063485 external-priority patent/WO2017091661A1/en
Publication of JP2019501140A publication Critical patent/JP2019501140A/ja
Publication of JP2019501140A5 publication Critical patent/JP2019501140A5/ja
Priority to JP2021078741A priority Critical patent/JP7112567B2/ja
Application granted granted Critical
Publication of JP6882289B2 publication Critical patent/JP6882289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018527799A 2015-11-25 2016-11-23 二環式ｂｅｔブロモドメイン阻害剤及びその使用 Active JP6882289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078741A JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259894P 2015-11-25 2015-11-25
US62/259,894 2015-11-25
PCT/US2016/063485 WO2017091661A1 (en) 2015-11-25 2016-11-23 Bicyclic bet bromodomain inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078741A Division JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Publications (3)

Publication Number Publication Date
JP2019501140A JP2019501140A (ja) 2019-01-17
JP2019501140A5 true JP2019501140A5 (https=) 2020-01-09
JP6882289B2 JP6882289B2 (ja) 2021-06-02

Family

ID=57543210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018527799A Active JP6882289B2 (ja) 2015-11-25 2016-11-23 二環式ｂｅｔブロモドメイン阻害剤及びその使用
JP2021078741A Active JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078741A Active JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Country Status (8)

Country Link
US (2) US10508106B2 (https=)
EP (2) EP3380469B1 (https=)
JP (2) JP6882289B2 (https=)
CN (2) CN109641886B (https=)
AU (3) AU2016361441B2 (https=)
CA (1) CA3006300C (https=)
ES (2) ES3011058T3 (https=)
WO (1) WO2017091661A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
CN109111426B (zh) * 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
WO2019201296A1 (zh) * 2018-04-18 2019-10-24 南京明德新药研发有限公司 作为rho激酶抑制剂的吡唑类化合物
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
EP4424379A3 (en) * 2019-04-24 2024-10-30 Convergene Llc Small molecule bromodomain inhibitors and uses thereof
BR112021022099A2 (pt) * 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
CN114222741B (zh) * 2019-05-31 2025-12-30 奇斯药制品公司 作为p2x3抑制剂的吡啶并嘧啶类衍生物
EP4234548A4 (en) * 2020-10-20 2024-10-23 Suzhou Zelgen Biopharmaceutical Co., Ltd. SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, ITS PREPARATION METHOD AND ITS APPLICATION
WO2022161461A1 (zh) * 2021-01-29 2022-08-04 江苏先声药业有限公司 Sos1抑制剂及其制备方法和应用
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
EP4291195A4 (en) * 2021-02-11 2025-07-09 Medical College Wisconsin Inc SMALL MOLECULE INHIBITORS OF PBRM1-BD2
CN119630431A (zh) * 2022-08-26 2025-03-14 卫材R&D管理有限公司 抗体药物缀合物
WO2024235225A1 (zh) * 2023-05-15 2024-11-21 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
WO2025209570A1 (zh) * 2024-04-03 2025-10-09 北京大学 Bet抑制剂及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
FI940469L (fi) 1991-08-02 1994-02-01 Pfizer Kinoliinijohdannaisia immunostimulantteina
WO1999011658A1 (en) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
SE0102858D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4934432B2 (ja) * 2004-02-19 2012-05-16 レクサン ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体およびキナゾリン誘導体の治療への使用
KR100910333B1 (ko) * 2005-02-23 2009-07-31 시오노기세이야쿠가부시키가이샤 타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2006121767A2 (en) 2005-05-06 2006-11-16 Apath, Llc 4-aminoquinoline compounds for treating virus-related conditions
WO2008054599A2 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
US20080200458A1 (en) * 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
GB0705915D0 (en) * 2007-03-28 2007-05-09 Helperby Therapeutics Ltd New use
EP2152672A1 (en) * 2007-05-24 2010-02-17 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
JP5301456B2 (ja) * 2007-11-12 2013-09-25 Ｍｓｄ株式会社 ヘテロアリールオキシキナゾリン誘導体
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2566477B1 (en) * 2010-05-07 2015-09-02 GlaxoSmithKline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
US8933096B2 (en) * 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
AU2011289230B2 (en) 2010-08-13 2014-09-04 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
WO2012125913A1 (en) * 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Methods and use of bifunctional enzyme-building clamp-shaped molecules
GB201106799D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
KR20140048216A (ko) 2011-06-29 2014-04-23 오츠카 세이야쿠 가부시키가이샤 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법
EP2788332A1 (en) * 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US20130225611A1 (en) * 2011-12-09 2013-08-29 The Regents Of The University Of California Compositions and Methods for Reducing Cancer Cell Proliferation and Modulating Importin-Beta Function
US20130281397A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9201821B2 (en) * 2012-09-27 2015-12-01 Apple Inc. Interrupt timestamping
KR20150072412A (ko) * 2012-10-05 2015-06-29 리겔 파마슈티칼스, 인크. Gdf-8 억제제
US9977024B2 (en) * 2012-12-09 2018-05-22 The Scripps Research Institute Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines
WO2014100501A1 (en) * 2012-12-20 2014-06-26 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
JP6464139B2 (ja) * 2013-03-14 2019-02-06 コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ ブロモドメイン含有タンパク質の阻害のための方法および組成物
EP3010918B1 (en) * 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
CN106536507B (zh) * 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
US11034757B2 (en) * 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
JP6599908B2 (ja) * 2014-06-25 2019-10-30 サンフォード−バーンハム メディカル リサーチ インスティテュート ニューロテンシン受容体１の小分子アゴニスト
US10106507B2 (en) * 2014-08-03 2018-10-23 H. Lee Moffitt Cancer Center and Research Insitute, Inc. Potent dual BRD4-kinase inhibitors as cancer therapeutics
WO2016120808A1 (en) 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof
EP3072891A1 (en) * 2015-03-24 2016-09-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New Toll-Like Receptor 9 Antagonists
JP2018525345A (ja) * 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用

Similar Documents

Publication Publication Date Title
JP2019501140A5 (https=)
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
WO2008151304A8 (en) Selective inhibitors for cyclin-dependent kinases
MX2023002688A (es) Compuestos farmaceuticos de arilo, heteroarilo, y heterociclicos para el tratamiento de trastornos medicos.
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
WO2020212895A1 (en) Method and apparatus to facilitate the binding of the gap protein to the mutant ras protein by molecular agents to cure ras-mutation related cancers
UA108369C2 (uk) Піролопіримідини як інгібітори cdk4/6
JOP20200114A1 (ar) عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
JP2008523018A5 (https=)
WO2018023072A3 (en) Compounds and compositions and uses thereof
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
CN110891950A (zh) 一种三嗪化合物及其药学上可接受的盐
EP3666273A3 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
JP2019510075A5 (https=)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
DK1940826T3 (da) Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4
NO20090073L (no) 1,3-disubstitue 4-metyl-1H-pyrol-2-karboksamider og deres anvendelse for fremstlling av medikamenter
DK4205732T3 (da) Cannabinoidsammensætning og anvendelse deraf i fremstilling af lægemiddel til behandling af neurodegenerative sygdomme, såsom parkinsons sygdom og alzheimers sygdom
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
DE602007004881D1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel